Edition:
United States

LivaNova PLC (LIVN.OQ)

LIVN.OQ on NASDAQ Stock Exchange Global Select Market

84.68USD
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
$84.68
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
132,464
52-wk High
$88.42
52-wk Low
$47.01

Chart for

About

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company's segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.... (more)
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 50.97 17.28
EPS (TTM): -- -- --
ROI: -- 14.13 35.61
ROE: -- 16.74 17.17

BRIEF-Livanova To Acquire Tandemlife

* LIVANOVA PLC - LIVANOVA HAS AGREED TO PAY UP TO $250 MILLION FOR TANDEMLIFE

Feb 14 2018

BRIEF-Livanova Initiates Believe Aortic Heart Valve Study In The U.S., Canada

* LIVANOVA INITIATES BELIEVE AORTIC HEART VALVE STUDY IN THE U.S. AND CANADA

Jan 11 2018

BRIEF-LivaNova Commences Global Restore-Life Study For Treatment-Resistant Depression

* LIVANOVA COMMENCES GLOBAL RESTORE-LIFE STUDY FOR TREATMENT-RESISTANT DEPRESSION Source text for Eikon: Further company coverage:

Jan 04 2018

BRIEF-Livanova To Acquire Imthera Medical

* LIVANOVA PLC SAYS ENTERED INTO AN AGREEMENT TO ACQUIRE REMAINING OUTSTANDING INTERESTS IN IMTHERA MEDICAL, INC.

Dec 05 2017

BRIEF-Microport Scientific's unit buys CRM business from Livanova

* ‍Unit buys CRM business for initial consideration of US$190 million​ from Livanova PLC Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

Nov 20 2017

BRIEF-LivaNova Plc reports ‍Q3 diluted earnings per share were $0.57​

* LivaNova Plc - ‍Q3 2017 diluted earnings per share were $0.57​

Nov 02 2017

BRIEF-Livanova receives FDA approval for Vagus Nerve Stimulation Therapy system​

* Livanova receives FDA approvals for SenTiva device and next-generation VNS therapy programming system for treatment of epilepsy

Oct 09 2017

BRIEF-Livanova and Microport announce approval of Rega pacemakers by China FDA

* Livanova and Microport announce the approval of Rega pacemakers by the China Food and Drug Administration

Sep 27 2017

BRIEF-Livanova announces U.S. Launch of Optiflow Arterial Cannulae Family

* Says ‍received FDA 510(k) clearance for U.S. Market launch of its Optiflow Arterial Cannulae Family​ Source text for Eikon: Further company coverage:

Sep 25 2017

BRIEF-LivaNova ‍expects to achieve revenue growth in mid-single-digits in near term and high-single-digits in long term​

* LivaNova Plc - ‍Expects to achieve revenue growth in mid-single-digits in near term and high-single-digits in long term​

Sep 14 2017

Earnings vs. Estimates

No consensus analysis data available.